Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Howmedica to license bone cement from Orthovita:

This article was originally published in Clinica

Executive Summary

Howmedica is to license Orthovita's new bone cement technology in an exclusive worldwide agreement. The Rutherford, New Jersey-based company will work with Orthovita to complete the development of Orthocomp, which received a US patent in 1997. Orthovita, located in Malvern, Pennsylvania, is expected to submit a 510(k) for non-load bearing applications. It plans to submit an Investigational Device Exemption (IDE) for load-bearing indications and as an implant cement by the end of the year. Of the annual 650,000 worldwide joint replacement procedures, about 60% involve the use of bone cement.

You may also be interested in...



Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Manpower Not Materials Could Hold German COVID-19 Testing Back

Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.

Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.

Topics

UsernamePublicRestriction

Register

MT081763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel